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A single amino acid substitution, Gly185~ Val, in the
human P-glycoprotein (Pgp) was previously shown to
cause an altered pattern of drug resistance in cell lines
transfected with the MDRI eDNA carrying this muta-
tion. To further define the function of amino acid 185 in
the Pgp, the wild-type and the mutant Val185 Pgps were
expressed in 8m insect cells, and their biochemical
properties were compared. Verapamil- and colchicine-
stimulated ATPase activities were markedly increased
with concomitant increase in affinity for these com-
pounds with Gly185~ Val substitution in the Pgp. How-
ever, the vinblastine-stimulated ATPase activities of the
wild-type and Val185 Pgps were nearly identical. Be-
cause transport substrate-induced ATP hydrolysis is
generally thought to reflect transport function, these
data suggest that colchicine and verapamil are trans-
ported at an increased rate with Gly185~ Val substitu-
tion in the Pgp. These results also indicate that amino
acid 185 is involved in verapamil and colchicine, but not
in vinblastine, binding/transport. Kinetic analyses indi-
cate that cyclosporin A, an inhibitor ofPgp, binds to the
verapamil and vinblastine binding/transport site(s) in
the Pgp. Taken together, the results presented herein
reveal that the verapamil and vinblastine binding/trans-
port site(s) are in close proximity and that the cycles-
porin A binding site spans the common region of these
two drug binding/transport site(s) in the Pgp molecule.
Tumor cells undergoing chemotherapy often develop resist-
ance to a wide variety of anti-neoplastic drugs in the phenom-
enon known as multidrug resistance (MDR)l (1). Multidrug
resistant tumor cells frequently express large quantities of a
130-170-kDa membrane glycoprotein, referred to as P-glyco-
protein (Pgp), encoded by the MDR1 gene (2). Evidence sug-
gests that the human Pgp acts as an energy-dependent trans-
porter that extrudes from cells a spectrum of compounds and
drugs with diverse structure and function. The human Pgp is a
1280-amino acid polypeptide, with secondary structure pre-
dicted to have 12 transmembrane segments and 2 ATP binding
domains on the cytoplasmic side of the molecule. The human
Pgp shares considerable sequence and structure homology
with an ever-growing list of ATP-binding cassette transport
proteins (3).
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Direct interaction of photoaffinity analogs of chemothera-
peutic agents such as colchicine (4), Adriamycin (5), and vin-
blastine (6) with the Pgp has been reported. Mapping of the
drug binding site(s) in Pgp using photoaffinity analogs has
indicated that these sitets) are within or in close proximity to
the putative transmembrane segments of the molecule (7).
However, the transmembrane segments and amino acid resi-
dues of the Pgp involved in substrate binding and transport
have not been precisely identified. An understanding of the
molecular interactions of drugs with the Pgp would greatly
facilitate our ability to modulate its function. An approach most
commonly employed toward this end by several laboratories is
site-directed mutagenesis in combination with analyses of rel-
ative drug resistance in cells (8, 9). Although the information
obtained from these studies is valuable for understanding the
overall process of MDR, these assays do not accurately reflect
the transport function of the Pgp.
Recently, Scarborough and co-workers (10) have demon-
strated a drug-stimulated ATPase activity of the human Pgp
expressed in cultured Sf9 insect cells. Several laboratories have
subsequently shown the drug-stimulated ATPase activity in
mammalian cells constitutively expressing the Pgp (11-13).
Most importantly, the ability of a variety of compounds to
stimulate the Pgp ATPase activity has recently been directly
correlated with their transport by the Pgp (14). Thus, meas-
urements of the ATPase function of the Pgp may be used to
explore the possible molecular mechanism by which the Pgp
mediates drug transport.
Cells selected in vitro against any single drug from a diverse
group of lipophilic cytotoxic compounds usually develop cross-
resistance to other drugs in the group. Some multidrug-resist-
ant cell lines are significantly more resistant to the drug used
in their selection than to the other drugs (15, 16). Further
studies have suggested that a single amino acid substitution,
GIy185 ~ Val, in the human Pgp was responsible for the pref-
erential resistance of KB epidermoid carcinoma cells to colchi-
cine (15, 16, 34). However, it is not known how the ATPase
function of the Pgp is modulated by the Val substitution at
amino acid 185 in the polypeptide. In this paper, I report the
expression of wild-type Pgp and compare its functional proper-
ties with that of the Val 185 Pgp. The results reported here
suggest that the amino acid at position 185 in the Pgp is
involved in colchicine and verapamil but not in vinblastine
binding/transport. The results presented herein also indicate
the propinquity of binding/transport sitets) of verapamil, vin-
blastine, and cyclosporin A in the human Pgp.
EXPERIMENTAL PROCEDURES
Construction of Baculovirus Transfer Vector p VL1393/ MDRGa-
Standard recombinant DNA procedures were used to construct the
baculoviral transfer vector containing human wild-type MDR1 cDNA
for expression in SID insect cells (17). A 4.2-kbSacII-XhoI fragment of
the human MDR1 cDNA containing plasmid, pHaMDRGa, was kindly
providedby Dr. M. M. Gottesman (16). For the convenience ofsubclon-
ing, pHaMDRGa was first digested withXhoI and blunt-ended with the
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Klenow fragment of Escherichia coli DNA polym erase I. It was th en
reli gated in the pr esenc e of XbaI linker s . Th e resulting plasmid was
call ed pH aMDRGalXbaI. Employing th e pHaMDRGa plasmid as a tem -
plate and Pfu DNA polym erase, a fragmen t of - 1.2 kb was synt hes ized
by polym erase chain reaction with a n added BamHI site containing
mutagenized forward primer, 5 '-GCGGGATCCCGGGATGGATCTT-
GAAGG-3 ' , a nd a n EcoR I site containing rever se primer , 5' -TCTGAAT-
TCCAAATTTCCC-3' . Th is polym er ase chain reaction-amplified frag-
ment contained a BamHI site at th e 5 ' -end, th e ATG star t codon of th e
MDR1 gene, and ext ended up to th e EcoRI site at - 1.2 kb . Th is
fragment wa s digested with BamHI a nd EcoRI a nd ligated with th e
- 3.0-kb EcoRI-XbaI fragment isolated from th e above pHaMDRGa/
XbaI , in the presence of pVL1393 transfer vector pr eviously dig ested
wit h Bam HI and XbaI. Th e resulting construct, pVL1393/MD RGa, con-
tained the ent ire coding region of th e human MDR1 cDNA a nd was
seq uenced by the dideoxynucleot ide chain termination seque ncing pro-
cedure (8) with 8equenase 2.0 from U. 8 . Biochemical Corp . With t he
exception of two silent mu tat ions, one at codon 412 (GGC (Gly) to GGT
(Gly)) a nd a nother at codon 547 (CGC (Arg) to CGT (Argl) , th e entire
codin g sequence was identical to the previously repor ted seque nce
04, 15).
Production of Recombinan t Baculovirus Carryin g Wild-type MDR 1
eDNA-8m insect cells were cot ra ns fecte d wit h 0.5 IJ.g of BaculoGo ld
DNA a nd 5 IJ.g of pVL1393/MDRGa by th e calci um ph ospha te coprecipi-
tation method accordin g to th e protocol provided by the manufacturer
(Pha rMingen , San Diego, CAl. 5 day s after cotransfection, the cult ure
med ium was collected and used to infect 30 million 8m insect cells in a
162-cm2 flask. After 3 days of incubation at 27 °C, th e culture medium
was collected, and th e virus was concent ra te d by centrifugation a t
40 ,000 x g for 60 min. Th e virus pellet was resuspended in fresh Gr ace's
complete medium (19) a nd used to infect 5 million 8m insect cell s in a
25-cm 2 flask. After 4 days of incubation at 27 °C, th e spent medium was
collected, a nd the recombinant baculovirus wa s plaque purified usin g
sta nda rd procedures (Invitrogen ). Two rounds of plaque purification
were performed to eliminate th e polyh edrin-expressing baculovirus.
Two isolates of recombinant bac ulovirus carrying th e wild -typ e MDR1
cDNA , termed wild -type MDR1 BV 9 a nd 10 were chos en for the pr esent
study.
To en sure that these recombinant bac uloviruses contained th e wild-
type MDR 1 cDNA , thei r DNA was amplified by polym erase chain re-
action according to the protocol provided by the manufacturer (Invitro-
gen ), clone d into M13 bacteriophage vector, and seq ue nced around th e
regio n t hat codes for th e amino acid 185 in the Pgp. The res ults clearly
ind ica ted that these reco mb inant bac uloviruses were the wild -type
MDR1 BVs (da ta not shown).
Prepa ration of recombina nt bac ulov irus carrying the huma n MDRI
cDNA wit h VaPH5 subs titution in the exp ressed protein, termed in this
paper as Va PS5 MDR 1 BV, was previously descr ibed by Germa nn et al .
(20).
Viral Infections of Sf9 Insect Cells and Preparation of Insect Cell
Membrane F ra ction- Appr oxim ately 30 mill ion expo nentia lly growing
8m in sect cells were seeded in each 162-cm2 flask and infected with
wild-type MDR1 BV 9 a nd 10, Val ls5 MDR1 BV, or E. coli {3-ga lactosid-
ase cDNA containing bac ulovirus ({3-ga l BV). Th e virus was added to a
mu lt iplicity of infection of about 6 plaque-forming units per cell . Th e
flasks were incubated at 27 °C for 3 days. The membrane fraction from
th e infected cells was pr epared as pr eviously described (21).
Pgp ATPase Activity Determination-The Pgp ATP as e activity of th e
membranes wa s det ermined in th e presenc e of various drugs as pr evi-
ously described 00, 21, 22 ). Each of th e experiments shown in th e
figures wa s carried out 4-6 times using membranes pr epared from
different batches of cells, with essentially th e same results. The data
points indicate the average of duplicate det erminations in the individ-
ua l expe riments. Membranes pr epared from 8m in sect cell s infected
with {3-gal BV were us ed as control. Th ese membranes did not contain
any drug-stimulated ATPase activity .
SDS-PAGE, Im munoblotting, and Quantitati on of Pgp in Mem-
branes- Membrane suspensions were mixed with 8D8-PAGE dis aggre-
gation buffer, incubated for 20 min at room temperature, a nd th en
electrophores ed on 15 x 15 x 0.075-cm 7.5% acryla mide gels as previ-
ous ly described (23, 24 ). Transfer of protein s from the acrylamide gels
onto polyvinyl idene difluoride mem br an es and immu node tection we re
carried out as described by 8arkadi et al . (0). The prim a ry antibody
was Pgp -specific C2 19 antibody, a nd the secondary antibody was
horseradish per oxidase-conjugated a nti-mouse a ntibody from donk ey
(Amers harn Cor p). Th e peroxidase-lab eled blots were developed by th e
enhanced chemilumi nescence method, usin g the Amer sh am ECL kit.
Th e Pgp ba nds obtaine d on the fluorograrns were qua ntitated by vol-
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FIG. 1. Weste rn blot analysi s of membranes isolated from 8 m
cells infected with wild-type MDR1 BV and VaP"" MDR1 BV. Th e
8m in sect cells wer e infect ed with wild -typ e MDRI BV 9 a nd 10 a nd
Val lS5 MDR1 BV and incubated at 27 °C for 3 da ys. Th e membranes
were pr epared as described , and equa l a mounts of membrane pr otein
(20 IJ.gllane) wer e subjected to 8D8-PAGE and West ern blot a na lysis
using C-219 antibody as described under "Expe rime nta l Procedures :
Lanes 1, 4 , 7, 10, membranes from wild-typ e MDR1 BV 9-infected srs
cells; lanes 2, 5, 8, 11, membranes from wild-type MDR1 BV 10-infected
8m cells ; lan es 3, 6, 9 ,12, membranes from Val lS5 MDR1 BV-infected
8m cell s. Onl y th e - 130-kDa region of th e blot is shown. No antibody-
reactive materi al was seen else whe re in th e blots .
um e integration analysis using a Bio-Rad imaging densitomet er
(GS670), equipped wit h Molecu la r Analyst software version 1.1.
Protein Estimation-Protein in the mem br ane susp en sions was de-
te rmi ned by the meth od of Lowry et al. (25) as modified by Bensadoun
and Weinstein (26) usi ng bovine se ru m a lbumin as th e sta nda rd.
Materials -Tissue culture supplies were obtained from th e
Lin eberger Cancer Center Tissue Culture Facility at th e Univer sity of
North Carolina , Chapel Hill. Molecular biology reagents wer e from
Promega, Boehringer-M annheim , Stratag en e, and Bio 101. Bacul oGold
transfection kit was from Ph arMingen (Sa n Diego, CAl. Th e C2 19
a ntibody was from Signet (Boston, MA). Th e horser adi sh per oxidase-
conjugated a nti-mous e a ntibody a nd ECL detection kit were from
Amer sh am . Colchicine, verapamil , and vinbla st ine wer e from Sigma.
Cyclos pori n A was from Sandoz Pharmaceutical Inst itute (NJ).
RESULTS
Expression and Quantitation of Pgp in Sj9 Insect Cell Mem-
branes-Expression of human wild-type Pgp in insect cells was
examined by Western blot analysis, and the results are shown
in Fig . 1. sm insect cells were infected with wild-type MDRI
BV 9 and 10 and Val 18 5 MDR1 BV, and the membranes from 3
days post-i nfection were prepared (21, 22). The proteins in th e
membranes were se parated by SDS-PAGE gels, electrotrans-
ferred onto polyvin ylidene difluori de membranes, an d th en
probed with the Pgp-specific C219 monoclonal antibody as de-
scri bed under "Experimental Procedures." A single band of
approx imately 130 kDa was visible in membran es obtained
from sm insect cells infected wit h the wild-type MDRI BV 9
(Fig. 1, lanes 1, 4 , 7, and 10 ) and 10 (Fig. 1, lan es 2, 5,8, and
11). Th ese Pgps were termed wild-ty pe Pgp 9 and 10, respec-
t ively, both of which comigrated with the Val 185 Pgp (Fig. 1,
lan es 3, 6, 9, an d 12). No detectable C219 antibody-reactive
proteins were foun d in control membranes in which sm insect
cells were in fecte d wit h the f3-gal BV (data not shown). Thus,
sm insect cells infected with wild-type MDR1 BV isolates 9 and
10 produce the wild-type Pgps, which are indistinguishable
from the previously characterized Val 185 Pgp (20).
Ana lyses of several batches of membrane preparations indi-
cated that the amo unts of Pgp expressed were variable. Since
the objective of the present study was to measure th e func-
tional differences between the wild-type and the Val 185 Pgps ,
quantitative est imation of the amount of Pgp protein in these
membranes was essential. Although Pgps separated on SDS-
PAGE gels were stained with Coomassie Blue an d silver, quan-
t itation could not be performed beca use several non -Pgp pro-
tein band s were also observed in this region of th e gels. The
C219 monoclonal antibody-reactive hexap eptide epito pe (27) is
identical in the wild-type and Val18 5 Pgps. Thus, immunoblots
developed using the C219 antibody as the prim ary antibo dy
were used for quantitating the Pgps in equal amounts of sev-
eral membran e prepara tions (Fig. 1). Th e amount of Val185 Pgp
arbitrarily was consid ered 1 abso rba nce unit , and the amounts
of wild-type Pgp s were cal culated as mul tiples of the amount of
Val 185 Pgp. For exa mple, the amount of Val185 Pgp in lane 3
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FIG. 2. Effect of verapamil on the ATPase activity of the wild-
type and VaP85 Pgps, The wild-type Pgp 9- (0), wild-type Pgp 10- (e),
and Val'85 Pgp- 6 containing membranes were incubated with increas-
ing concentrations of verapamil and assayed for ATPase activity as
described under "Experimental Procedures." Each data point was the
average of duplicate determinations.
was considered 1 absorbance unit, and the amounts of Pgp in
lanes 1 and 2 were expressed relative to the amounts ofPgp in
lane 3. Thus, the average values of 4 determinations indicated
that the wild-type Pgp 9 and 10 were 1.89 and 1.58 times the
amount of Val l8S Pgp (data not shown). These quantitative
measurements would not distinguish between functionally ac-
tive and inactive forms of the Pgps (see "Discussion").
Drug-stimulated Pgp ATPase Activities-The membrane
preparations used for quantitating the Pgp protein as shown in
Fig. 1 were used for the following studies. Fig. 2 shows the
effects of verapamil on the Pgp ATPase activities in the wild-
type Pgp- and Val l8S Pgp-containing membranes. The drug-
stimulated ATPase activity obtained with 1 mg of membrane
protein containing Val l8S Pgp was considered due to 1 unit of
Pgp. The drug-stimulated ATPase activities of the wild-type
Pgp 9 and 10 were normalized to the amounts of Val l8S Pgp
protein. Verapamil-stimulated wild-type Pgp ATPase activities
increased in a concentration-dependent manner. These Pgps
exhibited a maximum ATPase activity of approximately 26
nmol of Pi released per min per unit of Pgp at 500 /LM vera-
pamil; greater concentrations inhibited ATPase activity (not
shown). Control experiments indicated that the stimulation of
wild-type Pgp ATPase activity by verapamil was inhibited by
vanadate (l00 /LM) and unaffected by ouabain (1 mxr), sodium
azide (5 msr), or EGTA (2 mx). The Ka (half-maximal ATPase
activating concentration) value for verapamil calculated from
the double-reciprocal plots of six different determinations using
membranes containing wild-type Pgp 9 and 10 was 4.4 2:: 0.8
/LM (data not shown). However, the verapamil-stimulated
ATPase activity ofVall8s Pgp reached maximum at about 20
/LM, with a K a value of 1.0 2:: 0.2 /LM (six determinations). These
results suggest that verapamil interacts with Val l8S Pgp with
an affinity about 4 times higher than with the wild-type Pgp.
Colchicine stimulated ATPase activity of the wild-type Pgp 9
and 10, and at 400 /LM, these activities reached a maximum of
about 8 nmol of Pi released per min per unit of Pgp (Fig. 3). A
Ka value of 163 2:: 18 /LM was calculated from the double-
reciprocal plots of five different determinations. The Val l8SPgp
exhibited a maximal ATPase activity in the presence of colchi-
cine of about 25 nmol of Pi released per min per unit of Pgp,
with a Ka of approximately 67 2:: 9 /LM (five determinations).
These results suggest that replacement of Glyl8S with Val in
the Pgp increases the affinity for colchicine by more than 2-fold.
Vinblastine markedly increased the rate of ATP hydrolysis
by the wild-type and Val l8S Pgps (Fig. 4). Both forms of Pgp
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FIG. 3. Effect of colchicine on the ATPase activity of the wild-
type and Val18 5 Pgps, The wild-type Pgp 9- (0), wild-type Pgp 10- (e),
and Val 185 Pgp- (6) containing membranes were incubated with in-
creasing concentrations of colchicine and assayed for ATPase activity as
described under "Experimental Procedures." Each data point was the
average of duplicate determinations.
exhibited nearly identical maximum ATPase activity of approx-
imately 13 nmol of Pi released per min per unit of Pgp in the
presence of vinblastine. The K; for vinblastine calculated from
double-reciprocal plots of four determinations was 0.45 ± 0.06
/LM. These data suggest that mutation at amino acid 185 in the
Pgp polypeptide does not alter the affinity for vinblastine.
Although the above data suggest that the mutation Glyl85~
Val in the Pgp alters the affinity for verapamil and colchicine,
it does not rule out the possibility that the affinities for ATP
binding are responsible for these results. However, measure-
ments using increasing concentrations of Mg·ATP on the drug-
stimulated Pgp ATPase activities yielded identical Km values of
0.62 mM for Mg·ATP with both Pgp forms (data not shown).
These results indicate that the mutation at amino acid 185 in
the Pgp does not affect nucleotide binding.
We have shown recently that cyclosporin A inhibits vera-
pamil- and vinblastine-activated Val l85 Pgp ATPase activities
in a competitive manner, with K, values of approximately 20 nM
(22). In the present study, the interaction of cyclosporin A with
the wild-type Pgp in the presence of the above drugs was
analyzed (Fig. 5). Verapamil- and vinblastine-stimulated wild-
type Pgp ATPase activities were inhibited by cyclosporin A, and
the double-reciprocal plots suggested that the inhibition was
competitive (Fig. 5, insets). The K, for cyclosporin A in the
presence of both of these drugs was 150 ± 10 nM (four deter-
minations). Thus, the affinity for cyclosporin A was increased
by more than seven times with Glyl85 ~ Val mutation in the
Pgp molecule.
DISCUSSION
The colchicine-induced mutation in the MDR1 gene bestows
upon transfected cell lines a selective resistance to this drug
(15,16,34). Although the biochemical properties of the Val l85
Pgp are known mainly through the work from the laboratories
of Gottesman (20) and Scarborough (l0, 21, 22), it is not known
how the Glyl85 to Val mutation alters the ATPase function of
the Pgp. The results presented here indicate that the wild-type
human Pgp expressed in sm cells exhibits drug-stimulated
ATPase activity.
To critically examine any functional differences between the
wild-type and Val l85 Pgps, it is necessary to present the drug-
stimulated ATPase activity data obtained with equal amounts
ofPgp protein in these membranes. Although the densitometric
analysis employed to quantitate the Pgps in the membranes is
reliable, it does not discriminate functional from nonfunctional
Pgp proteins in the membrane preparations. Several functional
FIG. 5. Kinetics of inhibitions of the verapamil- and vinblas-
tine-stimulated wild-type Pgp ATPase activity by cyclosporin A.
The verapamil (panel A) or vinblastine (panel B) concentration was
varied, with constant cyclosporin A concentrations of 0 (0), 0.2 (e), and
0.4 fLM (A.). Insets, double-reciprocal plots of the data.
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elude cyclosporins, interact with Pgp with high affinity but fail
to elicit ATP hydrolysis. However, the cyclosporins act as com-
petitive inhibitors of transport substrate-induced ATP hydrol-
ysis (22). The data shown in Fig. 5 indicate that cyclosporin A
also inhibits verapamil- and vinblastine-stimulated wild-type
Pgp ATPase activities in a competitive manner. The simple
interpretation of these observations is that cyclosporin A binds
to the verapamil and vinblastine binding/transport sitets). In-
terestingly, the affinity for cyclosporin A increased markedly
with GlyI85 --> Val substitution, suggesting that amino acid 185
is involved in the cyclosporin A interactions with the Pgp.
These results may bear in an important way on the issue of
number and location of drug binding/transport sites in the Pgp
molecule. There may be two drug binding/transport sites in the
Pgp that are distinguishable by the presence or absence of
amino acid 185, one site to which both verapamil and colchicine
bind and a second to which vinblastine alone binds. Because
the verapamil- and vinblastine-stimulated Pgp ATPase activi-
ties were inhibited by cyclosporin A, the verapamil and vin-
blastine binding/transport sites are probably in close proxim-
ity, and cyclosporin A binds to the common region of both of
these sites. Alternatively, amino acid 185 is not in the drug
Human P-glycoprotein ATPase Activity
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photoaffinity ATP and drug analogs are available, which may
prove to be valuable in quantitating the amounts of Pgp in the
membrane preparations (28-30). However, it is not clear how
the Gly185 --> Val mutation regulates the interactions of these
photoaffinity analogs with the Pgp. Thus, to minimize this
uncertainty, two isolates of wild-type MDRI BVs, which ex-
press different amounts of the wild-type Pgps, were employed
in the present study. As shown in Figs. 2-4, the drug-stimu-
lated ATPase activities of the two wild-type Pgps were nearly
identical, indicating that the densitometric quantitation of
Pgps employed is dependable. In addition, the kinetic param-
eters K m , Ka , and K i , which do not depend on the enzyme
concentration, are suitable for describing the functionally dif-
ferent Pgp preparations.
The results presented in Figs. 2 and 3 indicate that the
interactions of Pgp with verapamil and colchicine are affected
by the mutation at amino acid 185 in the polypeptide. The
distinctly different activation profiles of Pgp ATPase and K a
values for these drugs suggest that replacement of GlyI85 with
Val leads to higher affinity interactions with the Pgp. Impor-
tantly, the increase in colchicine-induced Val 185 Pgp ATPase
activity compared with that of the wild-type Pgp directly cor-
relates with the increase in drug resistance imparted by the
mutation GlyI85 to Val in the Pgp molecule (15,16). Homolya et
al. (14) have recently demonstrated that only those compounds
that stimulate ATP hydrolysis are transported by the Pgp.
Furthermore, solubilized transport ATPases display ATP hy-
drolysis-coupled conformational changes, substrate binding,
and dissociation, indicating the complete catalytic cycle (31-
33). Thus, the Pgp ATPase activity induced by a drug is a direct
measure of its transport.
The vinblastine-stimulated ATPase activity profiles and the
Ka values obtained with the wild-type and Val
185 Pgps are
nearly identical, indicating that GlyI85 is not involved in vin-
blastine binding/transport. In contrast, the relative drug resist-
ance of transfected cell lines suggested that GlyI85 --> Val
substitution in the Pgp slightly increases the sensitivity to
vinblastine (15, 16). These data would be consistent with the
hypothesis that there may be an additional non-Pgp-mediated
resistance mechanism for vinblastine action, which could ac-
count for these observations (15).
We have shown recently that there are two classes of sub-
strates for Pgp. The first group interacts with the Pgp and
elicits ATPase activity, implying that these drugs are trans-
ported by the Pgp. The second class of compounds, which in-
2 3 4 5 6 7 8 9 10
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FIG.4. Effect of vinblastine on the ATPase activity of the wild-
type and VallS. Pgps, The wild-type Pgp 9- (0), wild-type Pgp 10- (e),
and Val1 8 S Pgp- (6) containing membranes were incubated with in-
creasing concentrations of vinblastine and assayed for ATPase activity
as described under "Experimental Procedures." Each data point was the
average of duplicate determinations.
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binding/transport sitets), but mutations at this residue bring
about conformational changes that impose different con-
straints on the Pgp, leading to altered patterns of affinity and
ATPase activity with different drugs. Further studies aimed at
characterizing the drug binding/transport site(s) of the Pgp
should enable us to better define the mechanism of MDR in
tumor cells.
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